The role of Ga-68 DOTATOC PET/CT in the detection of primary tumors in CUP-syndrome of neuroendocrine tumors (NETs)

2009 ◽  
Vol 47 (06) ◽  
Author(s):  
S Strobel ◽  
W Bohle ◽  
TM Welzel ◽  
WG Zoller ◽  
T Eichele ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Cup Syndrome ◽  
Primary Tumors ◽  
Pet Ct

scholarly journals Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT

2021 ◽  
Author(s):  
Stefan A. Koerber ◽  
R. Finck ◽  
K. Dendl ◽  
M. Uhl ◽  
T. Lindner ◽  
...  
Keyword(s):  
Hybrid Imaging ◽  
Background Activity ◽  
The Novel ◽  
Malignant Tissue ◽  
Primary Tumors ◽  
Aggressive Disease ◽  
Standardized Uptake Values ◽  
Pet Ct ◽  
Pet Scans

Abstract Purpose A high expression of fibroblast activation protein (FAP) was observed in multiple sarcomas, indicating an enormous potential for PET/CT using 68Ga-radiolabeled inhibitors of FAP (FAPI). Therefore, this retrospective study aimed to evaluate the role of the novel hybrid imaging probe for sarcomas as a first clinical evaluation. Methods A cohort of 15 patients underwent 68Ga-FAPI-PET/CT for staging or restaging. The acquisition of PET scans was performed 60 min after administration of 127 to 308 MBq of the tracer. The uptake of 68Ga-FAPI in malignant tissue as well as in healthy organs was quantified by standardized uptake values SUVmean and SUVmax. Results Excellent tumor-to-background ratios (> 7) could be achieved due to low background activity and high SUVmax in primary tumors (median 7.16), local relapses (median 11.47), and metastases (median 6.29). The highest uptake was found for liposarcomas and high-grade disease (range 18.86–33.61). A high SUVmax (> 10) was observed for clinically more aggressive disease. Conclusion These preliminary findings suggest a high potential for the clinical use of 68Ga-FAPI-PET/CT for patients diagnosed with sarcoma.

scholarly journals The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors

2014 ◽  
Vol 100 (4) ◽  
pp. 293-299 ◽  
Author(s):  
Stefano Partelli ◽  
Maria Rinzivillo ◽  
Angela Maurizi ◽  
Francesco Panzuto ◽  
Matteo Salgarello ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
Pancreatic Neuroendocrine Tumors ◽  
Pet Ct ◽  
Fdg Pet Ct

Role of 68ga-dotatoc pet/ct in the management of neuroendocrine tumors

2020 ◽  
Author(s):  
Laura Hernández-Montoliu ◽  
Inmaculada Peiró ◽  
Vercher Jose Luis ◽  
Judith Suils ◽  
Alexandre Teulé ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Pet Ct

scholarly journals The role of 18FDG PET/CT in evaluation of unknown primary tumors

2019 ◽  
Vol 70 (1) ◽  
pp. 39-42
Author(s):  
Bogdan Marković ◽  
Dragana Šobić-Šaranović
Keyword(s):  
Unknown Primary ◽  
Primary Tumors ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Unknown Primary Tumors

scholarly journals The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors

2012 ◽  
Vol 53 (11) ◽  
pp. 1686-1692 ◽  
Author(s):  
A. R. Haug ◽  
R. Cindea-Drimus ◽  
C. J. Auernhammer ◽  
M. Reincke ◽  
B. Wangler ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Pet Ct

The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors

2017 ◽  
Vol 38 (2) ◽  
pp. 170-177 ◽  
Author(s):  
Mohamad Haidar ◽  
Ali Shamseddine ◽  
Emmanouil Panagiotidis ◽  
Mario Jreige ◽  
Deborah Mukherji ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Pet Ct

scholarly journals Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT

2014 ◽  
Vol 48 (4) ◽  
pp. 339-347 ◽  
Author(s):  
Nils Friedemann Schreiter ◽  
Ann-Mirja Bartels ◽  
Vera Froeling ◽  
Ingo Steffen ◽  
Ulrich-Frank Pape ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Clinical Efficacy ◽  
Unknown Primary ◽  
Primary Tumors ◽  
Pet Ct ◽  
Clinical Verification

Abstract Background. To evaluate the clinical efficacy of In-111 DTPA octreotide SPECT/CT and Ga-68 DOTATOC PET/CT for detection of primary tumors in patients with either neuroendocrine tumor of unknown primary (NETUP) or clinically suspected primary NET (SNET). Patients and methods. A total of 123 patients were included from 2006 to 2009, 52 received Ga-68 DOTATOC PET/CT (NETUP, 33; SNET, 19) and 71 underwent In-111 DTPA octreotide SPECT/CT (50; 21). The standard of reference included histopathology or clinical verification based on follow-up examinations. Results. In the NETUP group Ga-68 DOTATOC detected primaries in 15 patients (45.5%) and In-111 DTPA octreotide in 4 patients (8%) (p < 0.001); in the SNET group, only 2 primaries could be detected, all by Ga-68 DOTATOC. In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01). Out of these 21 patients 14 patients were operated. Conclusion. Ga-68 DOTATOC PET/CT is preferable to In-111 DTPA octreotide SPECT/CT when searching for primary NETs in patients with NETUP but should be used with caution in patients with SNET.

Role of pet/ct in detection of tumor of unknown origin

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khadija R Elsayed ◽  
Khaled E Allam ◽  
Omar F Kamel ◽  
Ahmed H Soliman ◽  
Huda F Elsayed
Keyword(s):  
Primary Tumor ◽  
Predictive Value ◽  
Unknown Origin ◽  
Whole Body ◽  
Unknown Primary ◽  
Primary Tumors ◽  
Negative Results ◽  
Number Of Patients ◽  
Pet Ct

Abstract Purpose To evaluate the role of combined positron emission tomography and computed tomography (PET/CT) imaging in the detection of tumors of unknown origin. Methods This study included 20 cases presented with pathologically proved metastases of unknown primary or with clinic-radiological suspicion of metastases with unknown primary. Results The number of patients with true positive primary tumor sites was 14 (70%), 2 patients with false-positive results (10%), 2 patients with true negative results (10%) and 2 patients with false-negative results (10%). A sensitivity of 87.5% was achieved, with a specificity of 50% and a total accuracy of 80%. The Positive predictive value was 87.5%%, while the negative predictive value was 50%. The detection rate of the origin of the primary tumor was 70%. Conclusion whole-body FDG-PET/CT has to be considered a useful tool in evaluating metastases from UPT, allowing identification of primary tumors and modifying the stage of the disease and affect the management.

Sign in / Sign up

Export Citation Format

Share Document